New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 26, 2013
18:58 EDTSIGA, PIPSIGA says court reverses 'equitable payment stream' to PharmAthene
SIGA Technologies (SIGA) reported that the Delaware Supreme Court reversed the award of an "equitable payment stream" by the Court of Chancery in its May 31, 2012 Final Order and Judgment in PharmAthene (PIP) v. SIGA Technologies and also remanded the case to the Court of Chancery for further proceedings to determine appropriate damages. William J. Haynes II, SIGA's General Counsel, commented, "We are pleased with the Delaware Supreme Court ruling issued on Friday. The Supreme Court's decision states that PharmAthene may only obtain damages for its lost expectancy if it can prove them 'with reasonable certainty.' We intend to establish to the Chancery Court, consistent with that Court's earlier conclusions, that PharmAthene's evidence of expectancy damages is speculative and too uncertain, contingent, and conjectural to permit an award." Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, "While legal proceedings may continue, we will now focus with even greater intensity on growing and enhancing SIGA's business, executing our existing contract with BARDA, seeking approval and licensing of Arestvyrô from the U.S. Food and Drug Administration, and making greater use of our proven antiviral drug discovery and development capabilities."
News For SIGA;PIP From The Last 14 Days
Check below for free stories on SIGA;PIP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
09:25 EDTPIP, SIGAOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTSIGASIGA Technologies files petition for relief to supply Tecovirimat
Subscribe for More Information
September 11, 2014
07:25 EDTPIPAegis to hold a conference
Subscribe for More Information
September 10, 2014
09:07 EDTPIPPharmAthene awarded $28.1M contract by NIAID
Subscribe for More Information
September 9, 2014
09:08 EDTPIPPharmAthene presented non-clinical animal data on SparVax anthrax vaccine
PharmAthene announced that recent non-clinical animal data from its SparVax anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, DC. In a poster presentation Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax, when comparing survival and toxin neutralization assay results from the nonclinical anthrax aerosol challenge model.
September 8, 2014
10:14 EDTPIPPharmAthene, Nanotherapeutics form alliance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use